Empowered Funds LLC Acquires New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Empowered Funds LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 121,446 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,693,000.

Other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. grew its stake in Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares during the period. Vanguard Group Inc. grew its position in shares of Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after buying an additional 64,958 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after buying an additional 113,300 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. HC Wainwright upped their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Trading Down 2.3 %

NASDAQ:COLL opened at $29.58 on Monday. The stock has a market capitalization of $953.96 million, a price-to-earnings ratio of 12.75 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 52 week low of $24.61 and a 52 week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a 50 day moving average of $36.36 and a 200 day moving average of $35.01.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 15.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.